Newfeed

SINGAPORE, July 16, 2024 /PRNewswire/ — Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has approved the initiation o

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: